Treatment of HER2-Negative EBC

CE / CME

Expert Review of Treatment for HER2-Negative Early Breast Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 31, 2023

Expiration: August 30, 2024

Kevin Kalinsky
Kevin Kalinsky, MD, MS

Activity

Progress
1
Course Completed

American Cancer Society: Health Equity in Precision Medicine

We will end by talking about incorporating the patient voice to individualize, improve, and promote equity in patient care.

The American Cancer Society has highlighted health equity in precision medicine, and it is important that we address this.62 Despite evidence demonstrating the effectiveness of biomarker testing and targeted therapy, not all individuals benefit equitably from these advances. Improving access to biomarker testing is important for advancing health equity.

Need for Expanded Enrollment of Black People and Other Minorities in Clinical Trials

We need to expand the enrollment of black and other minority patients on clinical trials. As you can see listed on this slide, several racial and ethnic minority populations are significantly underrepresented, with trial enrollment numbers half or less than would be proportionate to US demographic populations.63 For us to achieve true precision medicine, it is imperative to increase diversity among enrollees to all clinical trials.

Tool: Healthcare Professional Checklist for Patient Communication in HER2-Negative EBC

A tool is available from CCO on key topics to review and discuss with all patients with HER2-negative EBC. The aim is to help facilitate equitable and inclusive communication, including ensuring that appropriate clinical trial options are made available to each patient. If we are not approaching patients about doing the appropriate testing, then they will not have the opportunity to opt in or opt out of either SoC or clinical trials.